CHMA Chiasma Inc.

3.99
0  0%
Previous Close 3.99
Open 4
Price To Book 1.97
Market Cap 168,600,071
Shares 42,255,657
Volume 424,623
Short Ratio
Av. Daily Volume 356,939
Stock charts supplied by TradingView

NewsSee all news

  1. Chiasma Enters Into Revenue Interest Financing Agreement for up to $75 Million with Healthcare Royalty Partners

  2. Chiasma Reports Fourth Quarter and Full Year 2019 Financial Results

    MYCAPSSA® PDUFA Date Set for June 26, 2020; U.S. Commercial Launch Planned in Q4'20 First Industry Sponsored U.S. Disease State Registry for Acromegaly Began Enrolling Patients NEEDHAM, Mass., March 16, 2020 (GLOBE

  3. Chiasma To Report Fourth Quarter and Full Year 2019 Financial Results On March 16, 2020

    NEEDHAM, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases,

  4. Chiasma Announces FDA Acceptance of MYCAPSSA® New Drug Application Resubmission

    FDA sets PDUFA date of June 26, 2020 Acceptance follows December 26, 2019 NDA resubmission NEEDHAM, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company

  5. Chiasma Provides Corporate Update and Previews 2020 Milestones

    MYCAPSSA® NDA resubmitted to FDA; PDUFA decision expected mid-2020 MYCAPSSA® U.S. commercial launch planned for the fourth quarter of 2020 Top-line MYCAPSSA® MPOWERED Phase 3 results on track for the fourth quarter of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date June 26, 2020.
Mycapssa - OPTIMAL
Acromegaly
CRL April 15 2016
Mycapssa
Acromegaly
Phase 3 data due 4Q 2020.
Mycapssa - MPOWERED
Maintenance treatment of adult acromegaly

Latest News

  1. Chiasma Enters Into Revenue Interest Financing Agreement for up to $75 Million with Healthcare Royalty Partners

  2. Chiasma Reports Fourth Quarter and Full Year 2019 Financial Results

    MYCAPSSA® PDUFA Date Set for June 26, 2020; U.S. Commercial Launch Planned in Q4'20 First Industry Sponsored U.S. Disease State Registry for Acromegaly Began Enrolling Patients NEEDHAM, Mass., March 16, 2020 (GLOBE

  3. Chiasma To Report Fourth Quarter and Full Year 2019 Financial Results On March 16, 2020

    NEEDHAM, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases,

  4. Chiasma Announces FDA Acceptance of MYCAPSSA® New Drug Application Resubmission

    FDA sets PDUFA date of June 26, 2020 Acceptance follows December 26, 2019 NDA resubmission NEEDHAM, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company

  5. Chiasma Provides Corporate Update and Previews 2020 Milestones

    MYCAPSSA® NDA resubmitted to FDA; PDUFA decision expected mid-2020 MYCAPSSA® U.S. commercial launch planned for the fourth quarter of 2020 Top-line MYCAPSSA® MPOWERED Phase 3 results on track for the fourth quarter of

  6. Chiasma Added to NASDAQ Biotechnology Index

    NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  7. Chiasma to Present at the Piper Jaffray 31st Annual Healthcare Conference

    WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  8. Chiasma to Present at the 13th Acromegaly Consensus Conference

    WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  9. Chiasma Reports Third Quarter 2019 Results

    CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints MYCAPSSA® NDA on track for submission by year-end 2019 MPOWEREDTM Phase 3 trial, designed to

  10. Chiasma Supports Acromegaly Awareness Day

    WALTHAM, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  11. Chiasma to Present at the Cantor 2019 Global Healthcare Conference

    WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  12. Chiasma Hosting Key Opinion Leader Meeting on Maintenance Therapy of Adult Patients with Acromegaly

    WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, will host a

  13. Chiasma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today

  14. Aleta Biotherapeutics Announces Appointments to Board of Directors

    Mark Leuchtenberger joins Board as Executive Chairman Eva-Lotta Allan appointed as Non-Executive Director Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular